DeuterOncology to Present Promising Phase I DO-2 MET Kinase Inhibitor Data at WCLC 2025
DO-2 is a best-in-class MET kinase inhibitor that has completed enrollment in a Phase 1 dose escalation study
Tumor shrinkage was observed in 100% of MET exon 14 skip NSCLC patients without additional oncogenic drivers, at doses that achieved preclinically defined thresholds
DO-2 has a very good safety profile with minimal peripheral oedema and clean safety profile compared to competitors
Liège, Belgium, September 9, 2025 – DeuterOncology, a clinical-stage biotech company focused on developing best-in-class deuterated cancer therapies, today announcing compelling safety, pharmacokinetic and efficacy results from its ongoing Phase I dose escalation study of DO-2, a novel deuterated MET tyrosine kinase inhibitor. The results are being presented at the World Conference on Lung Cancer (WCLC) 2025 in Barcelona (Abstract ID-2859).
